N/A N=50 Physical Activity After a Normal Spontaneous or Cesarean Delivery
Postpartum Disorder
Primary: Steps — 968; 1771; 1652; 3165 Steps — p=0.002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=1,114 Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine
Influenza
Primary: Immune Response: Age 18-49 — 28.8; 21.3; 55.2; 45.0 Anti-body response (GMT)
Phase 2 N=47 Effects of Broccoli Sprout Extract on Allergy Rhinitis
Rhinitis,Allergic
Primary: Total Nasal Symptom Score (TNSS) Change From Baseline to 3 Weeks of Randomly Assigned Treatment — -.5277; -.5484; -.8359; -.181 score on a scale
Phase 2 N=272 Lorcaserin in the Treatment of Cocaine Use Disorder
Cocaine-Related Disorders
Primary: The Primary Endpoint is the Actual Number of Subjects That Successfully Achieve Abstinence From Cocaine During the Last Three Weeks of Treatment in the "Pre-qualified…
Phase 2 N=42 Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
Cancer of the Breast
Primary: Percentage of Patients With Pathological Complete Response (pCR) in Patients Who Have Fatty Acid Synthase (FASN) Expression — 72.4 percentage of participants
Phase 2 N=41 A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale
Osteoarthritis, Knee
Primary: Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period — -12.6; -13.6; -11.7; -2.3 Scores on a scale
N/A N=101 Canadian Pradaxa Acute Stroke Safety Study
Ischemic Attack, Transient · Stroke
Primary: Symptomatic Hemorrhagic Transformation Rate (PH2) — 0; 0 Participants
Phase 3 N=52 Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration · Wet Macular Degeneration
Primary: Change in Mean Central Subfield Thickness (CST) — -36.6; 1.7 microns — p=0.04
Phase 3 N=744 Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
Amyotrophic Lateral Sclerosis
Primary: Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC) — -14.354; -12.648; -13.742; -13.927 %…
N/A N=106 Hepatic Effects of Gastric Bypass Surgery
Liver Diseases
Primary: Aspartate Transaminase (AST) Change — -6.32 U/L — p=0.03
N/A N=103,048 Pragmatic Trial of Video Education in Nursing Homes
Alzheimer Disease · Dementia · Heart Failure
Primary: Hospital Transfer Rate in Target Cohort — 2.4; 2.8 person-years
Phase 1 N=39 Immunotherapy of Stage III/IV Melanoma Patients
Melanoma
Primary: Change From Baseline in Mean Number of Adverse Events (Serious and Non Serious Events) — 13.40; 18.40; 23.80; 19.60 Number of adverse events
N/A N=3,230 Effect of Emergency Department Care Reorganization on Door-to-antibiotic Times for Sepsis (LDS SWARM)
Septic Shock · Sepsis
Primary: Time From ED Arrival to Administration of First Dose of Antibiotics — 173; 165; 169; 163 minutes — p=0.29
N/A N=74 Axis™ Allograft Dermis for Female Pelvic Floor Repair: a Prospective Post Market Study
Pelvic Organ Prolapse
Primary: Percentage of Participants With POP-Q Stage Improvement Assessed by POP-Q Stage Improvement Based Upon Grading of Prolapse of the Anterior, Posterior, or Combined…
N/A N=184 Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
Bleeding
Primary: Calculated Blood Loss — 1996 milliters